A Discussion on TCM Treatment and the Pathogenesis of Membranous Nephropathy in Primary Nephrotic Syndrome

抗癌研究 Pub Date : 2022-07-27 DOI:10.26689/par.v6i4.4173

Xin Li, Genping Lei

{"title":"A Discussion on TCM Treatment and the Pathogenesis of Membranous Nephropathy in Primary Nephrotic Syndrome","authors":"Xin Li, Genping Lei","doi":"10.26689/par.v6i4.4173","DOIUrl":null,"url":null,"abstract":"Objective: To investigate the TCM treatment principle of membranous nephropathy and its effect. Methods: A total of 56 patients were selected from the Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine. They were then divided into the control group (western medicine standard therapy) and the study group (Qidi Gushen prescription), with 28 patients in each group. The treatment effect, treatment safety, and patients’ satisfaction were observed and compared between the two groups. Results: The results showed that the treatment effect of the study group was 96.43%, which was significantly better compared with the control group (75.00%) (p < 0.05); in terms of safety, the probability of adverse events was 7.14% in the study group and 32.14% in the control group, in which the difference was statistically significant (p < 0.05); in addition, the study group’s satisfaction with the treatment measures was significantly higher than that of the control group (p < 0.05). Conclusion: In treating membranous nephropathy, traditional Chinese medicine can be tailored to its pathogenesis, which is not only beneficial to the treatment effect, but also has a high safety profile.","PeriodicalId":61025,"journal":{"name":"抗癌研究","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"抗癌研究","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.26689/par.v6i4.4173","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To investigate the TCM treatment principle of membranous nephropathy and its effect. Methods: A total of 56 patients were selected from the Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine. They were then divided into the control group (western medicine standard therapy) and the study group (Qidi Gushen prescription), with 28 patients in each group. The treatment effect, treatment safety, and patients’ satisfaction were observed and compared between the two groups. Results: The results showed that the treatment effect of the study group was 96.43%, which was significantly better compared with the control group (75.00%) (p < 0.05); in terms of safety, the probability of adverse events was 7.14% in the study group and 32.14% in the control group, in which the difference was statistically significant (p < 0.05); in addition, the study group’s satisfaction with the treatment measures was significantly higher than that of the control group (p < 0.05). Conclusion: In treating membranous nephropathy, traditional Chinese medicine can be tailored to its pathogenesis, which is not only beneficial to the treatment effect, but also has a high safety profile.

查看原文本刊更多论文

原发性肾病综合征膜性肾病的中医治疗及病机探讨

目的:探讨膜性肾病的中医治疗原则及疗效。方法:选取陕西中医药大学附属医院56例患者。将患者分为对照组(西药标准疗法)和研究组(七地固肾方)，每组28例。观察并比较两组患者的治疗效果、治疗安全性及患者满意度。结果:研究组治疗有效率为96.43%，显著优于对照组(75.00%)(p < 0.05);安全性方面，研究组不良事件发生概率为7.14%，对照组为32.14%，差异有统计学意义(p < 0.05);此外，研究组对治疗措施的满意度显著高于对照组(p < 0.05)。结论:中药治疗膜性肾病可因地制宜，不仅有利于治疗效果，而且具有较高的安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

抗癌研究

自引率

0.00%

发文量

135